Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Common Equity (2016 - 2025)

Historic Common Equity for Abvc Biopharma (ABVC) over the last 14 years, with Q3 2025 value amounting to $14.5 million.

  • Abvc Biopharma's Common Equity rose 78260.48% to $14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 78260.48%. This contributed to the annual value of $1.2 million for FY2024, which is 218.06% down from last year.
  • According to the latest figures from Q3 2025, Abvc Biopharma's Common Equity is $14.5 million, which was up 78260.48% from $9.5 million recorded in Q2 2025.
  • Abvc Biopharma's 5-year Common Equity high stood at $14.5 million for Q3 2025, and its period low was -$379315.0 during Q2 2023.
  • Over the past 5 years, Abvc Biopharma's median Common Equity value was $3.2 million (recorded in 2022), while the average stood at $5.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first soared by 170901.61% in 2022, then tumbled by 10406.37% in 2023.
  • Abvc Biopharma's Common Equity (Quarter) stood at $8.9 million in 2021, then crashed by 63.52% to $3.2 million in 2022, then tumbled by 61.27% to $1.3 million in 2023, then decreased by 2.18% to $1.2 million in 2024, then surged by 1081.98% to $14.5 million in 2025.
  • Its Common Equity was $14.5 million in Q3 2025, compared to $9.5 million in Q2 2025 and $8.0 million in Q1 2025.